BACKGROUND: remodeling of the mitral annulus contributes to progression of mitral regurgitation (MR). In patients withmoderate-to-severe MR, short-term treatment with β-blockers has been shown to increase left ventricular (LV) end-diastolic and end-systolic volume, and this could deleteriously increase mitral valve annular dimensions. The objective of this study was to quantify the effects of a short duration of β-blocker treatment on mitral annular dimensions and dynamics in patients with MR due to primary degenerative valve disease. METHODS AND RESULTS: twenty-five patients with moderate-to-severe degenerative MR and normal LV systolic function were studied in a double-blind crossover experiment using a β1-selective adrenergic blocker and placebo administered for 14±3 days. Cardiac MRI images were acquired after each treatment period to quantify mitral annular dimensions. At end diastole, there was no change in annular area (1659±331 versus 1632±299 mm(2); P<0.19), annular perimeter (154.3±16.4 versus 152±13.9 mm; P<0.13), septal-lateral (SL) dimension (38.0±5 versus 39.0±4.5 mm; P<0.15), or annular height (9.8±3.8 versus 9.5±2.5 mm; P<0.53). β-blockade resulted in significant end-diastole decreases in commissure-commissure dimension (48.9±4.6 versus 47.2±4.0 mm; P<0.01) and eccentricity (1.3±0.2 versus 1.2±0.1; P<0.01). At end systole (ES), β-blockade conferred a small, but significant decrease in annular perimeter (161.0±19.3 versus 156.8±16.9 mm; P<0.04) and eccentricity (1.2±0.1 versus 1.1±0.1; P<0.02), and the SL dimension significantly increased (41.5±5.7 versus 43.0±5.3 mm; P<0.03). Commissure-commissure dimension, annular area, and annular height at ES were not significantly different. CONCLUSIONS: despite significant increases in LV end-diastolic and end-systolic volume, short-term β-blocker treatment of patients withmoderate-to-severe MR reduced or preserved all mitral annular dimensions except SL at ES.
RCT Entities:
BACKGROUND: remodeling of the mitral annulus contributes to progression of mitral regurgitation (MR). In patients with moderate-to-severe MR, short-term treatment with β-blockers has been shown to increase left ventricular (LV) end-diastolic and end-systolic volume, and this could deleteriously increase mitral valve annular dimensions. The objective of this study was to quantify the effects of a short duration of β-blocker treatment on mitral annular dimensions and dynamics in patients with MR due to primary degenerative valve disease. METHODS AND RESULTS: twenty-five patients with moderate-to-severe degenerative MR and normal LV systolic function were studied in a double-blind crossover experiment using a β1-selective adrenergic blocker and placebo administered for 14±3 days. Cardiac MRI images were acquired after each treatment period to quantify mitral annular dimensions. At end diastole, there was no change in annular area (1659±331 versus 1632±299 mm(2); P<0.19), annular perimeter (154.3±16.4 versus 152±13.9 mm; P<0.13), septal-lateral (SL) dimension (38.0±5 versus 39.0±4.5 mm; P<0.15), or annular height (9.8±3.8 versus 9.5±2.5 mm; P<0.53). β-blockade resulted in significant end-diastole decreases in commissure-commissure dimension (48.9±4.6 versus 47.2±4.0 mm; P<0.01) and eccentricity (1.3±0.2 versus 1.2±0.1; P<0.01). At end systole (ES), β-blockade conferred a small, but significant decrease in annular perimeter (161.0±19.3 versus 156.8±16.9 mm; P<0.04) and eccentricity (1.2±0.1 versus 1.1±0.1; P<0.02), and the SL dimension significantly increased (41.5±5.7 versus 43.0±5.3 mm; P<0.03). Commissure-commissure dimension, annular area, and annular height at ES were not significantly different. CONCLUSIONS: despite significant increases in LV end-diastolic and end-systolic volume, short-term β-blocker treatment of patients with moderate-to-severe MR reduced or preserved all mitral annular dimensions except SL at ES.
Authors: Jos J M Westenberg; Rob J van der Geest; Hildo J Lamb; Michel I M Versteegh; Jerry Braun; Joost Doornbos; Albert de Roos; Ernst E van der Wall; Robert A E Dion; Johan H C Reiber; Jeroen J Bax Journal: Circulation Date: 2005-08-30 Impact factor: 29.690
Authors: Tom C Nguyen; Akinobu Itoh; Carl J Carlhäll; Wolfgang Bothe; Tomasz A Timek; Daniel B Ennis; Robert A Oakes; David Liang; George T Daughters; Neil B Ingels; D Craig Miller Journal: J Thorac Cardiovasc Surg Date: 2008-09 Impact factor: 5.209
Authors: Masao Daimon; Giuseppe Saracino; A Marc Gillinov; Yasushi Koyama; Shota Fukuda; Jun Kwan; Jong-Min Song; Vorachai Kongsaerepong; Deborah A Agler; James D Thomas; Takahiro Shiota Journal: Echocardiography Date: 2008-01-03 Impact factor: 1.724
Authors: Ralph A H Stewart; Owen C Raffel; Andrew J Kerr; Ruvin Gabriel; Irene Zeng; Alistair A Young; Brett R Cowan Journal: Circulation Date: 2008-08-25 Impact factor: 29.690
Authors: Benjamin M White; Anand Santhanam; David Thomas; Yugang Min; James M Lamb; Jack Neylon; Shyam Jani; Sergio Gaudio; Subashini Srinivasan; Daniel Ennis; Daniel A Low Journal: Med Phys Date: 2014-04 Impact factor: 4.071
Authors: Werner Budts; Jolien Roos-Hesselink; Tanja Rädle-Hurst; Andreas Eicken; Theresa A McDonagh; Ekaterini Lambrinou; Maria G Crespo-Leiro; Fiona Walker; Alexandra A Frogoudaki Journal: Eur Heart J Date: 2016-01-18 Impact factor: 29.983
Authors: Yuanjia Zhu; Annabel M Imbrie-Moore; Robert J Wilkerson; Michael J Paulsen; Matthew H Park; Y Joseph Woo Journal: BMC Cardiovasc Disord Date: 2022-02-26 Impact factor: 2.298
Authors: Pau Medrano-Gracia; Brett R Cowan; Bharath Ambale-Venkatesh; David A Bluemke; John Eng; John Paul Finn; Carissa G Fonseca; Joao A C Lima; Avan Suinesiaputra; Alistair A Young Journal: J Cardiovasc Magn Reson Date: 2014-07-30 Impact factor: 5.364